PI3K/mTOR therapies, Companion Diagnostics
also earlier stages other cancers
Celcuity is seeking to extend the lives of cancer patients by translating discoveries of new cancer subtypes into expanded therapeutic options. Targeted therapies only work if they inhibit the target pathway driving the oncogenic process. Using their cellular analysis platform, CELsignia, Celcuity is unraveling the complex oncogenic activity that molecular tests cannot detect. The platform analyzes signal transduction activity in live tumor cells ex vivo so Celcuity can measure cumulative dynamic signaling and see activated cell pathways. With this information, Celcuity can identify patients who may benefit from a targeted therapy. Celcuity’s CELsignia tests are currently being evaluated in five clinical trials.